ORCID as entered in ROS
https://orcid.org/0000-0002-4895-7384
Select Publications
Conference Papers
, 2021, 'Improved clinical feasibility of total tumor burden quantification on 68Ga-PSMA-11 PET/CT through deep learning autosegmentation of organs for automatic physiological uptake removal', in JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC
, 2020, 'De-Intensification of Post-Prostatectomy Radiotherapy: A survey of clinician opinions', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 36 - 37, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000594482700013&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2020, 'TheraP: A randomised phase II trial of Lu-177-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results (ANZUP protocol 1603).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, presented at
, 2020, 'Updated results of a phase I/II prospective dose escalation trial evaluating safety and efficacy of combination Lu-177 PSMA 617 and idronoxil in men with mCRPC post androgen signalling inhibition and taxane chemotherapy (LuPIN trial).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, presented at
, 2020, 'Results of a phase I/II prospective dose-escalation trial evaluating safety and efficacy of combination 177LuPSMA-617 and NOX66 in men with mCRPC post androgen signalling inhibition and two lines of taxane chemotherapy (LuPIN trial)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at
, 2018, 'A Prospective Study of F-18 Fluoro-methyl-choline (FCH) And Ga-68 HBED-CC- (PSMA) in Men being Considered for Salvage Radiation Treatment for Biochemical Failure Post Radical Prostatectomy', in INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, ELSEVIER SCIENCE INC, TX, San Antonio, pp. S162 - S162, presented at
, 2018, 'A prospective, multinational comparison of multi-parametric and whole body magnetic resonance imaging (mp-MRI and WB-MRI) F-18 fluoro-methyl-choline (FCH) and Ga-68 HBED-CC-(PSMA) in high risk men being considered for salvage radiation treatment for biochemical failure post radical prostatectomy: Detection rates, management impact and treatment response.', in JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, PA, Philadelphia, presented at
, 2018, 'Modulation of PSMA expression by Androgen deprivation therapy (ADT): Serial PSMA PET in men with hormone sensitive, and castrate resistant prostate cancer commencing androgen blockade', in JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, PA, Philadelphia, presented at
, 2018, 'A phase I study of 177Lu-DKFZ PSMA 617 combined with the radiosensitizer idronoxil in men with metastatic castrate-resistant prostate cancer (mCRPC) (LuPin trial).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.TPS5088
, 2018, 'Determining optimal sequencing of anti-PD-1 and BRAF-targeted therapy: A phase II randomised study of neoadjuvant pembrolizumab with/without dabrafenib and trametinib (D plus T) in BRAF V600 mutant resectable stage IIIb/c/d melanoma (NeoTrio trial)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.TPS9604
, 2018, 'Utility of 1-year FDG-PET (PET) to determine outcomes from anti-PD-1 (PD1) based therapy in patients (pts) with metastatic melanoma (MM)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.9517
, 2017, 'A Phase II, Randomised, Open Label Study of Neoadjuvant Pembrolizumab with/without Dabrafenib and Trametinib (D plus T) in BRAF V600 Mutant Resectable Stage IIIB/C/D Melanoma (NeoTrio Trial)', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Madrid, presented at
, 2017, 'Phase 2 study of neoadjuvant dabrafenib plus trametinib (D plus T) for resectable stage IIIB/C BRAF V600 mutant melanoma', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Madrid, presented at
, 2017, 'Lutetium-177 labelled prostate-specific membrane antigen (PSMA) for metastatic castrate-resistant prostate cancer (MCRPC): a systematic review and meta-analysis', in INTERNATIONAL JOURNAL OF UROLOGY, WILEY, pp. 110 - 110, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000406683600308&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2017, 'LUTETIUM-177 LABELLED PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) ANTIBODY AND LIGANDS FOR THE TREATMENT OF METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC): A SYSTEMATIC REVIEW AND META-ANALYSIS', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 41 - 42, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000427541700048&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2017, 'Frusemide aids diagnostic interpretation of Ga-68-PSMA PET CT in men with Prostate cancer.', in JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, CO, Denver, presented at
, 2017, 'Impact of small node size on clinical interpretation of F18 FDG PET CT for primary head and neck SCC malignancy. Bad things can come in small packages.', in JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, CO, Denver, presented at
, 2017, 'Staging F-18-FDG PET/CT Influences the Melanoma Treatment Plan in Patients with (Micro) Satellites or In-Transit Metastases', in ANNALS OF SURGICAL ONCOLOGY, SPRINGER, WA, Seattle, pp. S131 - S131, presented at
, 2016, 'Australian multicentre evaluation of clinical management intent utilising Ga68-PSMA PET scans in patients with prostate cancer', in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, SPRINGER, SPAIN, Barcelona, pp. S165 - S165, presented at
, 2015, 'A comparison of the utility of F18 Choline and Ga68 PSMA PET/CT in identifying distant disease in high risk prostate cancer patients being considered for radical prostatectomy', in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, SPRINGER, GERMANY, Hamburg, pp. S380 - S380, presented at
, 2015, 'Prospective Comparison of the detection rate of 18F-Fluoromethylcholine and 68Ga-PSMA-HBED PET/CT in men with prostate cancer with rising PSA post curative intent therapy, being considered for targeted therapy', in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, SPRINGER, GERMANY, Hamburg, pp. S35 - S36, presented at
, 2015, 'Pilot introduction of the IASLC nodal classification system across EBUS-TBNA, CT and PET in staging of Non Small Cell Lung Cancer', in JOURNAL OF THORACIC ONCOLOGY, ELSEVIER SCIENCE INC, pp. S681 - S681, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000370365103281&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2015, 'Prospective comparison of the detection rate of F-18-Fluoromethylcholine and Ga-68-PSMA-HBED PET/CT in men with prostate cancer with rising PSA post curative treatment, being considered for targeted therapy', in BJU INTERNATIONAL, WILEY, AUSTRALIA, Cairns, pp. 29 - 29, presented at
, 2015, 'PET-PSMA IN PROSTATE CANCER: CHANGING OUR VIEW OF METASTATIC DISEASE', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, AUSTRALIA, Sydney, pp. 30 - 30, presented at
, 2015, 'USING COMPUTER VISION FOR DETERMINING BONE INVOLVEMENT FOR LYMPHOMA PATIENTS WITH PET-CT IMAGES', in INTERNAL MEDICINE JOURNAL, WILEY-BLACKWELL, pp. 2 - 2, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000353038000005&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2014, 'ATTENUATION CORRECTION IN MYOCARDIAL PERFUSION IMAGING: A COMPARATIVE STUDY BETWEEN PRONE AND CTAC', in INTERNAL MEDICINE JOURNAL, WILEY-BLACKWELL, pp. 19 - 19, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000334282000053&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2012, 'A COMPARATIVE EVALUATION OF PLANAR VS SPECT/CT IN THE ASSESSMENT OF SACROILIAC JOINT ACTIVITY', in INTERNAL MEDICINE JOURNAL, WILEY-BLACKWELL, pp. 37 - 37, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000307882100120&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2012, 'DETERMINING APPROPRIATE PROCESSING METHOD FOR SPECT DATA OF LYMPHOSCINTIGRAPHY SCANNING', in INTERNAL MEDICINE JOURNAL, WILEY-BLACKWELL, pp. 6 - 6, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000307882100018&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2012, 'QUANTITATIVE ANALYSIS OF BLOOD POOL SPECT IMAGES IN THE EVALUATION OF THE SACROILIAC JOINTS', in INTERNAL MEDICINE JOURNAL, WILEY-BLACKWELL, pp. 37 - 37, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000307882100121&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2011, 'CALARA - Compassionate ALARA', in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, SPRINGER, pp. S448 - S448, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000208619401785&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2011, 'Glossopharyngeal breathing causes lung perfusion changes in Extreme Breath Hold Divers', in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, SPRINGER, pp. S458 - S459, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000208619401833&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2011, 'DEVELOPMENT OF AN AGE AND SEX MATCHED NORMAL DATABASE FOR QUANTITATIVE SACROILIAC UPTAKE ON SPECT/CT Tc-99m-MDP BONE IMAGING', in INTERNAL MEDICINE JOURNAL, WILEY-BLACKWELL, pp. 24 - 24, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000292514200075&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2011, 'Transient Ischaemic Dilation on Tc99m Adenosine Myocardial perfusion Imaging is not due to left ventricular cavity dilation or stunning. Comparison of echocardiography and myocardial perfusion imaging', in EUROPEAN HEART JOURNAL SUPPLEMENTS, OXFORD UNIV PRESS, NETHERLANDS, Amsterdam, pp. A59 - A59, presented at
, 2006, 'Platelet activation, inflammation and cardiac dysfunction, and their relation to the extent of acute pulmonary embolism', in EUROPEAN HEART JOURNAL, OXFORD UNIV PRESS, SPAIN, Barcelona, pp. 295 - 295, presented at
, 2006, 'Reduced tricuspid annular motion and right ventricular myocardial tissue velocities predict the extent and resolution of acute pulmonary embolism', in EUROPEAN HEART JOURNAL, OXFORD UNIV PRESS, SPAIN, Barcelona, pp. 616 - 616, presented at
, 2001, 'A reversible regional wall motion abnormality on single day exercise Tc-99m sestamibi gated SPECT perfusion: Imaging predicts a high grade angiographic stenosis.', in JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, pp. 94P - 95P, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000168821900354&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2000, 'A new appraoch to the diagnosis of fat embolism.', in JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, pp. 326P - 326P, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000089892401309&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 1999, 'A novel view for the scintigraphic assessment of the elbow.', in JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, pp. 194P - 194P, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000080105800785&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 1998, 'Irinotecan (CPT-11): A preliminary investigation of the relationship between trough concentrations of the active metabolite, SN-38, and toxicity', in ANNALS OF ONCOLOGY, KLUWER ACADEMIC PUBL, pp. 59 - 59, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000074749600194&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Conference Posters
, 2022, 'MP51-03 DEVELOPMENT OF A NOVEL NOMOGRAM TO IDENTIFY CANDIDATES FOR EXTENDED PELVIC LYMPH-NODE DISSECTION IN PROSTATE CANCER USING MRI AND PSMA PET', Vol. 207, http://dx.doi.org/10.1097/ju.0000000000002626.03
, 2017, 'Patterns of failure on Ga PSMA (GaPSMA) and F18 FDG (FDG) PET CT in a prospective phase 2 trial of Lu-177 DKFZ PSMA 617 (LuPSMA) in men with castrate resistant metastatic prostate cancer (mCRPC)', IL, Chicago, Vol. 35, presented at 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, IL, Chicago, 02 June 2017 - 07 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.2562
Conference Abstracts
, 2024, 'Combining MRI PI-RADS and PSMA-PET/CT PRIMARY score in a composite (P) score for more accurate diagnosis of clinically significant prostate cancer', in EUROPEAN UROLOGY, ELSEVIER, Vol. 85, pp. S476 - S476
, 2024, 'Development and external validation of a novel nomogram to predict the probability of pelvic lymph-node metastases in prostate cancer patients using magnetic resonance imaging and molecular imaging with prostate-specific membrane antigen positron emission', in EUROPEAN UROLOGY, ELSEVIER, Vol. 85, pp. S483 - S484
, 2024, 'The early oncological effect of extended pelvic lymph node dissection in men with at PSMA PET/CT N0M0 intermediate/high-risk prostate cancer - an international cohort study', in EUROPEAN UROLOGY, ELSEVIER, Vol. 85, pp. S1263 - S1264
, 2023, 'PSMA PET Tumor-to-Salivary Gland Ratio to Predict Response to [177Lu]PSMA Radioligand Therapy: An International Multicenter Retrospective Study', in Journal of Nuclear Medicine, Vol. 64, pp. 1024 - 1029, http://dx.doi.org/10.2967/jnumed.122.265242
, 2022, 'Dual tracer PET using 68-Ga PSMA and 18-F FDG for staging prostate cancer: A systematic review', in BJU INTERNATIONAL, WILEY, AUSTRALIA, Gold Coast, Vol. 129, pp. 143 - 143, presented at Annual Scientific Meeting of the Urological-Society-of-Australia-and-New Zealand, AUSTRALIA, Gold Coast, 25 June 2022 - 28 June 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000808481200232&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2022, 'Is a biopsy necessary before offering a radical prostatectomy in all men? An analysis of the PI-RADS 4 & 5 lesions from the PRIMARY trial', in BJU INTERNATIONAL, WILEY, AUSTRALIA, Gold Coast, Vol. 129, pp. 160 - 161, presented at Annual Scientific Meeting of the Urological-Society-of-Australia-and-New Zealand, AUSTRALIA, Gold Coast, 25 June 2022 - 28 June 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000808481200262&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2022, '64Cu-SAR-Bombesin PET-CT imaging in the staging of ER+/PR+/HER2-metastatic breast cancer: Safety, dosimetry, and feasibility in a phase I trial.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 40, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022
, 2022, 'Circulating tumour cells (CTCs) and PSMA PET correlates in the phase I PRINCE trial of 177Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 40, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022
, 2022, 'PRINCE: Phase I trial of 177Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 40, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022
Filter by type
https://orcid.org/0000-0002-4895-7384